Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Seattle Genetics preps filing next year for oral HER2 drug

Seattle Genetics preps filing next year for oral HER2 drug

The HER2CLIMB trial evaluated tucatinib as an add-on therapy to Roche’s anti-HER2 antibody Herceptin (trastuzumab) plus Xeloda (capecitabine), and it found that the new drug achieved a 46% ... HER2CLIMB-02 will compare tucatinib to placebo in

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs It made just over $1bn in the first nine months of this year from its use in patients who relapse after or don’t respond to Herceptin. ... in order to move it into earlier lines of treatment so as to challenge Roche’s Herceptin/Perjeta duo.

Roche reports continued growth in Q3, despite biosimilar competition

Roche reports continued growth in Q3, despite biosimilar competition The uptake of new medicines has offset the decreased sales of Herceptin and Rituxan, which have lost their respective patents and so have faced competition from generic sales.

Leading AstraZeneca’s return to growth in Europe

Leading AstraZeneca’s return to growth in Europe s Herceptin.

Roche wins FDA breakthrough for Gazyva in lupus nephritis

Roche wins FDA breakthrough for Gazyva in lupus nephritis Roche has been counting on a new class of medicines to help offset the  biosimilar onslaught on its ageing cancer blockbusters, including Herceptin and MabThera/Rituxan.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics